The agency seeks comments through Nov. 8 on an external request to expand Medicare coverage for positron emission tomography (PET) tracers to agents that image beta-amyloid plaques to diagnose dementia and other neurogenerative diseases. CMS opened the national coverage analysis Oct. 9 in response to a June 29 letter from Eli Lilly & Co.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?